Immuron Limited reported that its Travelan® product line achieved double‑digit growth in the third quarter of fiscal 2026, with global sales rising 16% to AUD 1.5 million compared with the same period in the prior year.
Australian sales drove the majority of the increase, climbing 15% to AUD 0.9 million. The growth was attributed to intensified digital and social‑media marketing, stronger in‑store promotion, and expansion into new pharmacy banners, which broadened the product’s retail footprint.
U.S. sales grew modestly by 1% to AUD 0.5 million, a gain that was partially offset by a strengthening Australian dollar against the U.S. dollar. The company’s enhanced Amazon.com presence and targeted social‑media campaigns contributed to the uptick, but currency headwinds limited the net impact.
Canadian sales experienced an 82% sequential jump, driven by new retail listings and promotional activities in Quebec. However, year‑to‑date sales for March 2026 were down 65% compared with the prior comparable period, reflecting a difficult baseline from the previous year. The sequential improvement signals a rebound, but the overall decline underscores the need for continued market penetration.
Despite the revenue gains, Immuron remains unprofitable over the last twelve months and is rapidly burning through cash, as noted by market observers. The company’s cash position exceeds its debt, and its current ratio stands at 1.8, indicating short‑term liquidity but ongoing cash‑flow pressure.
The announcement also highlighted the company’s progress toward its Phase 2 clinical trial of IMM‑529, a novel therapy for Clostridioides difficile infection. The FDA’s approval of the investigational new drug application allows the trial to proceed in the first half of 2026, positioning Immuron to expand its product portfolio beyond the traveler’s‑diarrhea market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.